Prime Only Members-Only Article

What A ‘Forever War’ Against COVID Would Mean

In this photo Dec. 25, 2020 released by Xinhua News Agency, packages of COVID-19 inactivated vaccine products are seen at a production plant of the Beijing Biological Products Institute Co., Ltd, a unit of state-owned Sinopharm in Beijing. The Chinese drugmaker said Wednesday, Dec. 30, 2020 its coronavirus vaccine was found to be 79.3% effective at preventing infection in preliminary data from the final round of testing, moving Beijing closer to possibly being able to fulfill its pledge to supply other developing countries.(Zhang Yuwei/Xinhua via AP)
FILE - In this Dec. 25, 2020, file photo, released by Xinhua News Agency, packages of COVID-19 inactivated vaccine products are seen at a production plant of the Beijing Biological Products Institute Co., Ltd, a unit... FILE - In this Dec. 25, 2020, file photo, released by Xinhua News Agency, packages of COVID-19 inactivated vaccine products are seen at a production plant of the Beijing Biological Products Institute Co., Ltd, a unit of state-owned Sinopharm in Beijing. China has given conditional approval to a coronavirus vaccine developed by state-owned Sinopharm. The vaccine is the first one approved for general use in China.(Zhang Yuwei/Xinhua via AP, File) MORE LESS
By
|
February 3, 2021 6:07 p.m.

I wrote today about the prospect of COVID-19 becoming a “forever war,” with the response looking something more like a constant battle against a highly deadly flu virus, without its seasonal weaknesses.

It’s a grim but very real prospect.

Prime Only Members-Only Article
To access exclusive analysis and reporting from TPM’s award-winning staff along with:
The Hive Member Forum
Members-Only Newsletter
Exclusive RSS Feeds
Commenting
Prime
$60/yr
Access to member exclusives and fewer ads
Get Prime
Prime Ad Free
$100/yr
Access to member exclusives and NO ads
Get Prime AF
View All Options
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Senior Editor:
Special Projects Editor:
Investigations Desk:
Reporters:
Newswriters:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front-End Developer:
Senior Designer:
SPECIAL DEAL FOR PAST TPM MEMBERS
GET 30% OFF PRIME
Rejoin and get 30% off an annual membership
Rejoin and get 30% off an annual membership